Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".


►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.

Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central




Publication of the 2nd issue in 2019


Prof. Lieping Chen et al. published their work on immune suppressor Siglec-15 in Nature Medicine at the beginning of this year. According to this breakthrough research, Prof. Xiubao Ren accepted our invitation and contributed an editorial with perspective on a therapeutic application related to this new target. In this latest issue, you could appreciate Prof. Ren’s work and learn about his viewpoints.


Supporting by a large population study, Prof. Martha L. Slattery et al. composed a review which discusses the functional role of miRNAs and colorectal cancer. As for the results of original researches, including the molecular mechanisms in tumorigenesis or cancer development associated with signal pathways, the application of new drugs in cancer treatment, and so on, should be also useful and worthy of reading by oncologic clinicians and researchers.


We hope all of these articles will greatly benefit your research and clinical practice. Thank you for your attention and welcome to submit your work to Cancer Biology & Medicine.

Posted: 2019-05-14

Publication of the 1st issue in 2019


The 1st issue in 2019 has been published. An editorial and a Chinese expert consensus offer the advances and insights in clinical application of next-generation sequencing. Another editorial reports a breakthrough in in vitro expansion of human primary hepatocytes. Review of Jianguo Chen et al. shows the epidemiological trend and risk factors of liver cancer in Qidong, an area with high incidence. What’s more, two original researches from China are worthy of recommending. One study on reactive capillary hemangiomas from Xuelian Chen et al. could arouse an awareness of drug toxicities in immunotherapy. Another one written by Xiaohong Wu et al. reports that BRAF mutation and TIRADS classification could be as tools in diagnosis of papillary thyroid cancer. Besides, several latest results from basic and clinical researches were also presented, especially studies on signaling pathways. We hope all of these articles will greatly benefit your research and clinical practice.


Thank you for your attention and welcome to submit your work to Cancer Biology & Medicine.


Click here to read all the full texts for free.

Posted: 2019-02-15
More Announcements...

Cancer-related RNAs Collection (2017-2018)

The collection includes all the papers on cancer-related RNAs published by Cancer Biology & Medicine in 2017-2018

Table of Contents


Circular RNAs and human glioma PDF
Jinglei Liu, et al. 11-23
Aberrant expression of enzymes regulating m6A mRNA methylation: implication in cancer PDF
Natalia Pinello, et al. 323-334
Key questions about the checkpoint blockade-are microRNAs an answer? PDF
Mihnea Dragomir, et al. 103-115
Natural and artificial small RNAs: a promising avenue of nucleic acid therapeutics for cancer PDF
Sunny Yadav, et al. 242-253

Original Article

Knockdown of long non-coding RNA LCPAT1 inhibits autophagy in lung cancer PDF
Xiao Yu, et al. 228-237
LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214 PDF
Ying Chen, et al. 238-250
Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy PDF
Ye Tian, et al. 157-164
Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs PDF
Sumadi Lukman Anwar, et al. 387-395